

Docket Number: 037003-0280062

Client Reference: 2000-30-0178A



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re the Application of

NABIL HANNA

Group Art Unit: 1642

Application No.: 09/822,672

Examiner: Larry R. Helms

Filed: April 2, 2001

Confirmation No.: 9345

For: COMBINED USE OF ANTI-CYTOKINE ANTIBODIES OR ANTAGONISTS AND ANTI-CD20 FOR THE TREATMENT OF B CELL LYMPHOMA

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:


Pursuant to 37 CFR 1.56, the attention of the Patent and Trademark Office is hereby directed to the reference(s) listed on the attached PTO-1449. Unless otherwise indicated herein, one copy of each reference is submitted herewith. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the reference(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is being filed after filing a request for continued examination and before receipt of a subsequent official action on the merits. No certification or fee is required.

Respectfully Submitted,

Thomas A. Cawley, Jr., Ph.D,
Registration Number 40944

Date: June 1, 2004
PILLSBURY WINTHROP LLP
Telephone: (703) 905-2000
Facsimile: (703) 905-2500
P.O. Box 10500
McLean, VA 22102
TAC/JBM



FORM PTO-1449 (modified)

Atty. Dkt. No.
037003-0280062

Client Ref.
2000-30-0178A

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Applicant: HANNA et al.

Appln. No.: 09/822,672

Filing Date: April 02, 2001

Date: June 1, 2004

Page 1 of 1

Examiner: Larry R. Helms

Group Art Unit: 1642

U.S. PATENT DOCUMENTS

Examiner's Initials*		Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
	AR	5,595,721	01/1997	Kaminski			
	BR	5,639,600	06/1997	McGrath			
	CR	5,677,180	10/1997	Robinson			
	DR	5,716,612	02/1998	Rybak			
	ER	5,736,137	04/1998	Anderson			
	FR	5,770,190	06/1998	Bruserud			
	GR	5,837,293	11/1998	De Waal Malefyt			
	HR	5,871,725	02/1999	Schwarz			

FOREIGN PATENT DOCUMENTS

		Document Number	Date MM/YYYY	Country	Inventor Name		English Abstract	Translation Readily Available
	IR	WO00/20864	04/2000	PCT	Barbera-Guillem			
	JR	WO98/56418	12/1998	PCT	Lam			

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

	KR	Beatty PR et al., "Involvement of IL-10 in the autonomous growth of EBV-transformed B cell lines," <i>J Immunol</i> , 1997, 158: 4045-4051.
	LR	Bonavida B et al., "Synergy is documented in vitro with low-dose recombinant tumor necrosis factor, cisplatin, and doxorubicin in ovarian cancer cells," <i>Gynecol Oncol</i> , 1990, 38: 333-339.
	MR	Cortes J et al., "Interleukin-10 in non-Hodgkin's lymphoma," <i>Leuk Lymphoma</i> , 1997, 26: 251-9.
	NR	Dedoussis GV et al., "Endogenous interleukin 6 conveys resistance to cis-diamminedichloroplatinum-mediated apoptosis of the K562 human leukemic cell line," <i>Exp Cell Res</i> , 1999, 249: 269-278.
	OR	Hekman A et al., "Initial experience with treatment of human B cell lymphoma with anti-CD19 monoclonal antibody," <i>Cancer Immunol Immunother</i> , 1991, 32: 364-372.
	PR	Kiesel S et al., "Removal of cells from a malignant B-cell line from bone marrow with immunomagnetic beads and with complement and immunoglobulin switch variant mediated cytolysis," <i>Leuk Res</i> , 1987, 11: 1119-1125.
	QR	Mosmann TR et al., "Isolation of monoclonal antibodies specific for IL-4, IL-5, IL-6, and a new Th2-specific cytokine (IL-10), cytokine synthesis inhibitory factor, by using a solid phase radioimmunoassay," <i>J Immunol</i> , 1990, 145: 2938-2945.
	RR	Press OW et al., "Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas," <i>Blood</i> , 1987, 69: 584-591.
	SR	Stasi R et al., "Clinical implications of cytokine and soluble receptor measurements in patients with newly-diagnosed aggressive non-Hodgkin's lymphoma," <i>Eur J Haematol</i> , 1995, 54: 9-17.
	TR	Vlasveld LT et al., "Treatment of low-grade non-Hodgkin's lymphoma with continuous infusion of low-dose recombinant interleukin-2 in combination with the B-cell-specific monoclonal antibody CLB-CD19," <i>Cancer Immunol Immunother</i> , 1995, 40: 37-47.
	UR	Voorzanger N et al., "Interleukin (IL)-10 and IL-6 are produced in vivo by non-Hodgkin's lymphoma cells and act as cooperative growth factors," <i>Cancer Res</i> , 1996, 56: 5499-5505.
	VR	Wang Z et al., "Sensitization by interleukin-1alpha of carboplatinum anti-tumor activity against human ovarian (NIH:OVCAR-3) carcinoma cells in vitro and in vivo," <i>Int J Cancer</i> , 1996, 68: 583-587.
	WR	Yonish-Rouach E et al., "Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6," <i>Nature</i> , 1991, 352: 345-347.

	XR	<i>Idec Pharmaceuticals and Corixa Corp.</i> , Case No. 01-1637-IEG [Doc. Nos. 486, 584] (S.D. Cal. Oct. 14, 2003).
	YR	<i>Biogen Idec v. Corixa Corp.</i> , Case No. 01-1637-IEG [Doc. Nos. 635, 662, 486] (S.D. Cal. Jan. 22, 2004).
Examiner		Date Considered:
<p>*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.</p>		

